Nkarta, Inc. (NKTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US65487U1088
Nkarta, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -122.00 m USD |
| EBIT | -104.08 m USD |
| Net income | -104.08 m USD |
| Diluted EPS – continuing operations | -1.41 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
More stocks
- Piscines Desjoyaux SA (ALPDX.PA)
- Taiwan Television Enterprise Co.Ltd. (8329.TWO)
- Sedana Medical AB (SEDANA.ST)
- After You Public Company Limited (AU.BK)
- Emvision Medical Devices Ltd (EMV.AX)
- Miluna Acquisition Corp (MMTX)
- Hansol Holdings Co Ltd (004150.KS)
- Fast Ejendom (FED.CO)
- Sanitar Co Ltd (1817.TW)
- AUBURN NATIONAL BANCORPORATION, INC (AUBN)
- Groupe Minoteries SA (GMI.SW)
- Bflysoft Co. Ltd. (148780.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.